Vaxart Inc
Closed
0
Overview
Share price change
24h
Min
Max
Income | -50M 5.2M |
|---|---|
Sales | -65M 39M |
P/E Sector Avg | 4.063 51.415 |
EPS | 0.02 |
Profit margin | 13.203 |
Employees | 65 |
EBITDA | -53M 5.2M |
Next Earnings | 12 sie 2026 |
|---|
Market Cap | -27M 157M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Vaxart Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Vaxart Inc Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
